Specialty pharmaceutical company Pivotal Therapeutics has announced that its Vascazen – Reveal trial met its primary endpoint, the correction of omega-3 deficiency.

Vascazen also achieved statistical significance in different secondary endpoints in patients presenting with elevated triglycerides (>200mg/dL < 500mg/dL).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Vascazen is a prescription-only medical food, designed for the dietary management of an omega-3 deficiency in patients with cardiovascular conditions.

Pivotal chairman and chief scientific officer Dr George Jackowski said the results are significant milestone for Vascazen as a treatment option for Omega-3 deficient people suffering from elevated triglycerides that remain below the threshold of very high triglycerides required for treatment with currently available prescription medications.

"Vascazen is a prescription-only medical food, designed for the dietary management of an omega-3 deficiency in patients with cardiovascular conditions."

"This landmark study is among the first that examined Omega-3 deficiency pre and post-treatment and brings the importance of its correction to the forefront as an important part in managing CVD patients," Jackowski said.

See Also:

"We are very excited to be presenting our top line results at this premier conference as it attracts the top clinicians and scientists in all areas of cardiovascular disease focusing on lipids and heart disease."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The double-blind, placebo-controlled, multi-centre US-based study enrolled 110 patients.

The randomised study was designed to assess the effects of Vascazen in the correction of omega-3 deficiency in patients with one or more risk factors associated with CVD, and to assess Vascazen’s concomitant effects on cardiovascular risk factors.

Secondary endpoints of the study include positive effects on lipid profiles, without any adverse events.